Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 8 Active not recruiting 6 Completed 4 Withdrawn 3 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12 Gastrointestinal 5 Genitourinary 4 Tumor-Agnostic 3 Head & Neck 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 Classical hematology 1 CNS 1

Conditions

Glioblastoma 1 Brain Neoplasms 1

Interventions

Temozolomide 80 Radiotherapy 41 Bevacizumab 35 Radiosurgery 23 Magnetic Resonance Spectroscopy 20 Cyclophosphamide 17 Radiation 14 Irinotecan 13 Carboplatin 12 Topotecan 11 Nivolumab 11 Lomustine 11 Filgrastim 10 Everolimus 10 Etoposide 10 Erlotinib Hydrochloride 10 pembrolizumab 9 Radiotherapy, Intensity-Modulated 9 Ipilimumab 9 Granulocyte Colony-Stimulating Factor 8 Carmustine 8 antineoplaston AS 2-1 7 antineoplaston A10 7 Surgical Procedures, Operative 7 Mental Status and Dementia Tests 7 Isotretinoin 7 Granulocyte-Macrophage Colony-Stimulating Factor 7 sargramostim 6 Vincristine 6 TPI-287 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × abemaciclib × CNS × Clear all

NCT04074785 2025-08-17

SCCC-06319

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Terminated

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡